The September 2018 issue of Pharmafocus is available to read online now!
pharmafile | September 3, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance
The new September edition of Pharmafocus is now live and available to read online.
We’re entering the final stretch as Brexit looms with a divorce date set for March next year, but the majority of the work remains for Prime Minister Theresa May and her reshuffled cabinet in negotiations with the EU. With the details of any possible deal still to be defined, the resulting uncertainty is leading the industry to more strongly voice its concerns in a climate that currently makes it impossible to plan ahead. The Government has attempted to assuage these concerns with the release of guidance to provide direction to companies in the event of a “no deal” scenario. Perhaps unsurprisingly, it hasn’t proved reassuring, with some of the advice encouraging the stockpiling of medicines to mitigate a predicted shortfall. You can read the full story on our front page this month.
There have been other alarming developments as allegations emerge that pharmaceutical firms including AstraZeneca, Roche, Pfizer and Johnson & Johnson funded terror activity in Iraq during the war, by making corrupt payments to the nation’s health ministry while it was under control of the US-opposed Mahdi army. The US Department of Justice has launched an investigation into the claims, while it also becomes clear that the number of measles cases across Europe have surged, rising to 41,000 cases in 2018 so far compared to 24,000 the previous year, presenting a new challenge in the region.
We also have full-length features on drug safety and on the latest innovations in the diagnosis of cancer and the discovery of new drugs to fight the disease. And to coincide with Alzheimer’s Awareness Month, Roche and Genentech’s Dr Rachelle Doody discusses how past and current study findings are shaping the development of new therapies to fight the condition.
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
